Breaking Finance News

Northland Capital reiterated ValiRx PLC (LON:VAL) to Corporate in a report released today.

Northland Capital has reiterated ValiRx PLC (LON:VAL) to Corporate in a report released on 9/27/2016.

Yesterday ValiRx PLC (LON:VAL) traded 0.37% higher at 6.75GBX. The company’s 50-day moving average is 7.47GBX and its 200-day moving average is 8.87GBX. The last stock close price is down -23.59% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time. 208,164 shares of the stock were exchanged, down from an average trading volume of 921,828

See Chart Below


ValiRx PLC has a 52 week low of 5.75GBX and a 52 week high of 29.80GBX The company’s market cap is currently 0 GBX.

In addition to Northland Capital reporting its target price, a total of 1 firm has issued a report on the stock. The consensus target price is 1.05GBX with 0 firms rating the stock a strong buy, 0 firms rating the stock a buy, 0 firms rating the stock a hold, 0 firms rating the stock a underperform, and finally 0 firms rating the stock a sell.

About ValiRx PLC (LON:VAL)

ValiRx plc is a biopharmaceutical company. The principal activity of the Company is the development of oncology therapeutics and companion diagnostics. It focuses on the treatment of cancer and associated biomarkers, specializing in epigenomic and genetic analysis. It operates in two business segments: drug development and the sale of self-test drug kits. Its product pipeline includes VAL101, VAL201, VAL401 and Nav3. VAL201 is an anti-cancer therapeutic drug, which is in clinical trials for the treatment of prostate cancer and other indications of hormone induced unregulated growth including endometriosis. VAL401 is the reformulation of a generic drug for treatment of a chronic non-oncology disease in an oral capsule. VAL101 is a therapeutic based on its Gene Inactivation by chromatin engineering (GeneICE) platform. NAV3 Cancer Screening Test enables the detection of cancer cells in tissue samples. It operates through divisional companies, including ValiPharma, ValiFinn and ValiSeek.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *